SOURCE Generex Biotechnology Corporation
Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.
Biotech watchdog Adam Feuerstein answers readers' questions about drug and health care companies.
Generex Biotechnology is planning a reverse stock split to raise the price of its common stock and stave off delisting from the Nasdaq.
Our biotech watchdog answers readers' questions and tweets about drug- and health care-related stocks.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.